Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said a routine inspection of its wholly owned step-down subsidiary, Lannett Co. in Seymour, Indiana, by U.S. Food and Drug Administration, concluded with four observations.
The inspection was conducted from Aug. 17 to 21, according to a Monday filing on NSE. The company said the observations were procedural in nature and it will respond to the U.S. FDA within the specified timeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.